The company primarily focuses on the treatment of B-cell cancers such as multiple myeloma that originates in bone marrow and mantle cell lymphoma, one of the rarest forms of non-Hodgkin’s lymphoma. In addition to treating B-cell cancers, Senesco hopes its gene regulation product SNS01-T will help treat many other conditions, including diabetes and ischemia, as well as other types of cancer.
Last year, the company was granted orphan drug status of SNS01-T. The treatment helps regulate both lysine (protein that promotes cell death) and hypusine (protein that promotes cell growth).
Instead of focusing on treatments that slow the spread of cancerous cells to healthy cells or exclusively reduce existing tumors, Senesco Technologies has instead chosen to focus on delivering proteins already used by the body to fight and prevent cancerous cells from developing. This drug treatment would also help the body shut down existing cancer cells to prevent the spread of damaged cells to healthy cells.
With promising results from multiple pre-clinical trials using mice, Senesco launched a clinical trial for SNS01-T in the summer of 2012. Pre-clinical trials resulted in 85-95% growth inhibition in mice given bi-weekly doses of SNS01-T for a 6-week period.
Upon completion of this trial, Senesco hopes not only to have found a viable treatment for multiple types of cancer, but also a treatment that could be used to help fight other diseases and conditions.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2013 The Hygiology Post ®